Is UroGen Pharma Ltd (URGN) overvalued? · rev $123.4M
UroGen Pharma Ltd (URGN) is a biotechnology company listed on NASDAQ.
This page asks whether UroGen Pharma Ltd (URGN) looks expensive on cached numbers — not a short thesis.
Latest reported URGN revenue for 2026-06-30 was $123.4M. Net income was -$37.9M. URGN currently screens at market cap $1.61B.
URGN currently screens at market cap $1.61B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next URGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the URGN stock page for the full model, not this heading.
Not investment advice.